Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Granted Links QVAQMUAKTNUNLN-LURJTMIESA-N (4s)-4-amino-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)[C@@H](N)CCC(O)=O QVAQMUAKTNUNLN-LURJTMIESA-N 0.000 title claims abstract description 28 238000010189 synthetic method Methods 0.000 title description 6 238000006243 chemical reaction Methods 0.000 claims abstract description 50 238000000034 method Methods 0.000 claims abstract description 31 230000015572 biosynthetic process Effects 0.000 claims abstract description 26 238000003786 synthesis reaction Methods 0.000 claims abstract description 26 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 21 MJSHDCCLFGOEIK-UHFFFAOYSA-N benzyl (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OCC1=CC=CC=C1 MJSHDCCLFGOEIK-UHFFFAOYSA-N 0.000 claims abstract description 20 239000002253 acid Substances 0.000 claims abstract description 15 239000003054 catalyst Substances 0.000 claims abstract description 10 ZGEYCCHDTIDZAE-BYPYZUCNSA-N L-glutamic acid 5-methyl ester Chemical compound COC(=O)CC[C@H](N)C(O)=O ZGEYCCHDTIDZAE-BYPYZUCNSA-N 0.000 claims abstract description 8 238000007327 hydrogenolysis reaction Methods 0.000 claims abstract description 5 230000002194 synthesizing effect Effects 0.000 claims abstract description 5 230000009471 action Effects 0.000 claims abstract description 4 238000006555 catalytic reaction Methods 0.000 claims abstract description 3 OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 87 HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 78 YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 55 WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 52 XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48 ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 40 239000002904 solvent Substances 0.000 claims description 40 WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33 235000011121 sodium hydroxide Nutrition 0.000 claims description 25 YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 25 WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 24 GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 20 KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 16 CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 16 DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 16 230000035484 reaction time Effects 0.000 claims description 16 XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15 BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14 239000002585 base Substances 0.000 claims description 13 YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12 VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 12 LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11 239000003513 alkali Substances 0.000 claims description 10 SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 9 ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9 HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8 229910000029 sodium carbonate Inorganic materials 0.000 claims description 8 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7 235000011181 potassium carbonates Nutrition 0.000 claims description 7 235000017550 sodium carbonate Nutrition 0.000 claims description 7 JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6 150000001875 compounds Chemical class 0.000 claims description 4 230000003301 hydrolyzing effect Effects 0.000 claims description 4 QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4 UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3 239000000203 mixture Substances 0.000 claims description 3 239000011736 potassium bicarbonate Substances 0.000 claims description 3 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3 TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3 UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3 230000008569 process Effects 0.000 abstract description 12 238000001308 synthesis method Methods 0.000 abstract description 6 239000006227 byproduct Substances 0.000 abstract description 4 239000003814 drug Substances 0.000 abstract description 4 238000011031 large-scale manufacturing process Methods 0.000 abstract description 4 239000007791 liquid phase Substances 0.000 abstract description 4 229940079593 drug Drugs 0.000 abstract description 3 238000006460 hydrolysis reaction Methods 0.000 abstract description 2 QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 22 WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 17 WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 13 239000000758 substrate Substances 0.000 description 9 VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8 239000000047 product Substances 0.000 description 8 238000004128 high performance liquid chromatography Methods 0.000 description 7 239000012074 organic phase Substances 0.000 description 7 PAIRNPIFEFCXCR-UHFFFAOYSA-M sodium;ethyl acetate;hydroxide Chemical compound [OH-].[Na+].CCOC(C)=O PAIRNPIFEFCXCR-UHFFFAOYSA-M 0.000 description 7 GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 description 7 238000001228 spectrum Methods 0.000 description 7 238000004519 manufacturing process Methods 0.000 description 6 239000000243 solution Substances 0.000 description 6 RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4 229930195712 glutamate Natural products 0.000 description 4 235000013922 glutamic acid Nutrition 0.000 description 4 239000004220 glutamic acid Substances 0.000 description 4 239000007788 liquid Substances 0.000 description 4 230000014759 maintenance of location Effects 0.000 description 4 239000007864 aqueous solution Substances 0.000 description 3 230000009286 beneficial effect Effects 0.000 description 3 230000008901 benefit Effects 0.000 description 3 210000003169 central nervous system Anatomy 0.000 description 3 239000003153 chemical reaction reagent Substances 0.000 description 3 UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3 108090000765 processed proteins & peptides Proteins 0.000 description 3 239000002994 raw material Substances 0.000 description 3 238000000926 separation method Methods 0.000 description 3 239000000126 substance Substances 0.000 description 3 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3 QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2 UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2 238000007171 acid catalysis Methods 0.000 description 2 238000009835 boiling Methods 0.000 description 2 230000030833 cell death Effects 0.000 description 2 239000012141 concentrate Substances 0.000 description 2 238000002425 crystallisation Methods 0.000 description 2 230000008025 crystallization Effects 0.000 description 2 238000010586 diagram Methods 0.000 description 2 230000003492 excitotoxic effect Effects 0.000 description 2 210000001362 glutamatergic neuron Anatomy 0.000 description 2 230000020796 long term synaptic depression Effects 0.000 description 2 230000027928 long-term synaptic potentiation Effects 0.000 description 2 238000012986 modification Methods 0.000 description 2 230000004048 modification Effects 0.000 description 2 210000002569 neuron Anatomy 0.000 description 2 230000001575 pathological effect Effects 0.000 description 2 238000010647 peptide synthesis reaction Methods 0.000 description 2 239000003208 petroleum Substances 0.000 description 2 229920001184 polypeptide Polymers 0.000 description 2 KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2 102000004196 processed proteins & peptides Human genes 0.000 description 2 230000002035 prolonged effect Effects 0.000 description 2 238000000746 purification Methods 0.000 description 2 239000002351 wastewater Substances 0.000 description 2 208000024827 Alzheimer disease Diseases 0.000 description 1 201000006474 Brain Ischemia Diseases 0.000 description 1 SFWGLCGAZRNDOB-UHFFFAOYSA-L C(C)(=O)OCC.C([O-])([O-])=O.[K+].[K+] Chemical compound C(C)(=O)OCC.C([O-])([O-])=O.[K+].[K+] SFWGLCGAZRNDOB-UHFFFAOYSA-L 0.000 description 1 MKXDUHWVKNBGBE-UHFFFAOYSA-M CO.C([O-])(O)=O.[K+] Chemical compound CO.C([O-])(O)=O.[K+] MKXDUHWVKNBGBE-UHFFFAOYSA-M 0.000 description 1 206010008120 Cerebral ischaemia Diseases 0.000 description 1 206010008748 Chorea Diseases 0.000 description 1 102100039104 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Human genes 0.000 description 1 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1 102000018899 Glutamate Receptors Human genes 0.000 description 1 108010027915 Glutamate Receptors Proteins 0.000 description 1 101000884921 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Proteins 0.000 description 1 208000013016 Hypoglycemia Diseases 0.000 description 1 206010021143 Hypoxia Diseases 0.000 description 1 YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1 108010019598 Liraglutide Proteins 0.000 description 1 208000018737 Parkinson disease Diseases 0.000 description 1 ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1 DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1 208000006011 Stroke Diseases 0.000 description 1 241000251539 Vertebrata Species 0.000 description 1 XMLJCSFKQSJZLS-UHFFFAOYSA-L [K+].[K+].OC.[O-]C([O-])=O Chemical compound [K+].[K+].OC.[O-]C([O-])=O XMLJCSFKQSJZLS-UHFFFAOYSA-L 0.000 description 1 XYBHGJNPHFDGGU-UHFFFAOYSA-L [Na+].[Na+].OC.[O-]C([O-])=O Chemical compound [Na+].[Na+].OC.[O-]C([O-])=O XYBHGJNPHFDGGU-UHFFFAOYSA-L 0.000 description 1 230000002378 acidificating effect Effects 0.000 description 1 230000004913 activation Effects 0.000 description 1 235000001014 amino acid Nutrition 0.000 description 1 150000001413 amino acids Chemical class 0.000 description 1 125000003277 amino group Chemical group 0.000 description 1 229910021529 ammonia Inorganic materials 0.000 description 1 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1 238000004458 analytical method Methods 0.000 description 1 210000004556 brain Anatomy 0.000 description 1 BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1 230000003197 catalytic effect Effects 0.000 description 1 206010008118 cerebral infarction Diseases 0.000 description 1 230000008859 change Effects 0.000 description 1 239000007809 chemical reaction catalyst Substances 0.000 description 1 239000007795 chemical reaction product Substances 0.000 description 1 208000012601 choreatic disease Diseases 0.000 description 1 230000001054 cortical effect Effects 0.000 description 1 230000034994 death Effects 0.000 description 1 230000007423 decrease Effects 0.000 description 1 238000013461 design Methods 0.000 description 1 238000011161 development Methods 0.000 description 1 230000018109 developmental process Effects 0.000 description 1 235000014113 dietary fatty acids Nutrition 0.000 description 1 238000010790 dilution Methods 0.000 description 1 239000012895 dilution Substances 0.000 description 1 201000010099 disease Diseases 0.000 description 1 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1 YFSCLDWVNTUOOE-UHFFFAOYSA-L disodium ethyl acetate carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.CCOC(C)=O YFSCLDWVNTUOOE-UHFFFAOYSA-L 0.000 description 1 -1 dry Substances 0.000 description 1 230000000694 effects Effects 0.000 description 1 206010015037 epilepsy Diseases 0.000 description 1 HTYPUWWYCDTVRR-UHFFFAOYSA-N ethyl acetate;4-methylmorpholine Chemical compound CCOC(C)=O.CN1CCOCC1 HTYPUWWYCDTVRR-UHFFFAOYSA-N 0.000 description 1 OJAGAAVUZKMVGX-UHFFFAOYSA-N ethyl acetate;pyridine Chemical compound CCOC(C)=O.C1=CC=NC=C1 OJAGAAVUZKMVGX-UHFFFAOYSA-N 0.000 description 1 230000005284 excitation Effects 0.000 description 1 230000002964 excitative effect Effects 0.000 description 1 230000002461 excitatory amino acid Effects 0.000 description 1 239000003257 excitatory amino acid Substances 0.000 description 1 231100000063 excitotoxicity Toxicity 0.000 description 1 239000000194 fatty acid Substances 0.000 description 1 229930195729 fatty acid Natural products 0.000 description 1 150000004665 fatty acids Chemical class 0.000 description 1 238000001914 filtration Methods 0.000 description 1 239000012467 final product Substances 0.000 description 1 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1 ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1 230000000971 hippocampal effect Effects 0.000 description 1 238000005984 hydrogenation reaction Methods 0.000 description 1 230000007062 hydrolysis Effects 0.000 description 1 230000002218 hypoglycaemic effect Effects 0.000 description 1 230000007954 hypoxia Effects 0.000 description 1 230000006872 improvement Effects 0.000 description 1 208000014674 injury Diseases 0.000 description 1 229960002701 liraglutide Drugs 0.000 description 1 210000005171 mammalian brain Anatomy 0.000 description 1 CSYNQJPENMOLHR-UHFFFAOYSA-N n,n-diethylethanamine;ethyl acetate Chemical compound CCOC(C)=O.CCN(CC)CC CSYNQJPENMOLHR-UHFFFAOYSA-N 0.000 description 1 SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1 210000000478 neocortex Anatomy 0.000 description 1 210000004498 neuroglial cell Anatomy 0.000 description 1 239000002858 neurotransmitter agent Substances 0.000 description 1 239000003002 pH adjusting agent Substances 0.000 description 1 230000008506 pathogenesis Effects 0.000 description 1 230000004796 pathophysiological change Effects 0.000 description 1 230000037361 pathway Effects 0.000 description 1 230000035790 physiological processes and functions Effects 0.000 description 1 IXXZIVZAQDPMAI-UHFFFAOYSA-M potassium;ethyl acetate;hydrogen carbonate Chemical compound [K+].OC([O-])=O.CCOC(C)=O IXXZIVZAQDPMAI-UHFFFAOYSA-M 0.000 description 1 238000012545 processing Methods 0.000 description 1 230000035755 proliferation Effects 0.000 description 1 210000004129 prosencephalon Anatomy 0.000 description 1 125000006239 protecting group Chemical group 0.000 description 1 235000018102 proteins Nutrition 0.000 description 1 102000004169 proteins and genes Human genes 0.000 description 1 108090000623 proteins and genes Proteins 0.000 description 1 210000002763 pyramidal cell Anatomy 0.000 description 1 238000011160 research Methods 0.000 description 1 239000013557 residual solvent Substances 0.000 description 1 230000004044 response Effects 0.000 description 1 230000002441 reversible effect Effects 0.000 description 1 210000001202 rhombencephalon Anatomy 0.000 description 1 229950011186 semaglutide Drugs 0.000 description 1 108010060325 semaglutide Proteins 0.000 description 1 238000004904 shortening Methods 0.000 description 1 JWEBFZPSIPMEFI-UHFFFAOYSA-M sodium acetonitrile hydroxide Chemical compound [OH-].[Na+].CC#N JWEBFZPSIPMEFI-UHFFFAOYSA-M 0.000 description 1 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1 235000017557 sodium bicarbonate Nutrition 0.000 description 1 HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1 WINYCIXPFGVTOS-UHFFFAOYSA-M sodium;dichloromethane;hydroxide Chemical compound [OH-].[Na+].ClCCl WINYCIXPFGVTOS-UHFFFAOYSA-M 0.000 description 1 KUJFKFWQVGCSAR-UHFFFAOYSA-M sodium;ethyl acetate;hydrogen carbonate Chemical compound [Na+].OC([O-])=O.CCOC(C)=O KUJFKFWQVGCSAR-UHFFFAOYSA-M 0.000 description 1 RBLVMKIXRXHOLI-UHFFFAOYSA-M sodium;hydrogen carbonate;methanol Chemical compound [Na+].OC.OC([O-])=O RBLVMKIXRXHOLI-UHFFFAOYSA-M 0.000 description 1 FPTVEOPNJVOJBF-UHFFFAOYSA-M sodium;oxolane;hydroxide Chemical compound [OH-].[Na+].C1CCOC1 FPTVEOPNJVOJBF-UHFFFAOYSA-M 0.000 description 1 230000004083 survival effect Effects 0.000 description 1 210000000225 synapse Anatomy 0.000 description 1 230000000946 synaptic effect Effects 0.000 description 1 230000005062 synaptic transmission Effects 0.000 description 1 239000003053 toxin Substances 0.000 description 1 231100000765 toxin Toxicity 0.000 description 1 230000008733 trauma Effects 0.000 description 1 238000005406 washing Methods 0.000 description 1 Images Classifications CCHEMISTRY
These products typically contain dihydroxyacetone (DHA), an ingredient that reacts with amino acids in the outermost layer of the skin to create a temporary darkening effect
This means it stimulates GLP-1 receptors to reduce appetite and enhance insulin secretion, while blocking GIP signaling, which may help prevent fat storage
Signs of glycine toxicity include: Visual disturbances Drowsiness Vomiting Weakness Prickling skin sensations Skin flushing Glycine toxicity can be fatal
For pregnant women unable to quit smoking, daily doses of vitamin C may provide some protection to the developing foetus, a Portland, Oregon study suggests
